ClinicalTrials.gg
RecruitingNCT06704594BLOOMUpdated May 7, 2026

Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder

A Phase 4 interventional study of sertraline 50 mg daily and Placebo Oral Tablet in Premenstrual Dysphoric Disorder (PMDD), sponsored by Johns Hopkins University. Recruiting at 2 sites in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Johns Hopkins University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Premenstrual Dysphoric Disorder with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Premenstrual Dysphoric Disorder · United States.

Planned enrollment
2nd of 15
288 · median 45
Started
2025
with 1 other
Phase 4
5 of 19
1 open now
Registered
16th of 19
by date
Lead sponsor
2 of 19
Johns Hopkins University

Among the 19 studies in Premenstrual Dysphoric Disorder with a site in United States, this one is the 2nd largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 in phase 4, and was the 16th registered.

Premenstrual Dysphoric Disorder

42 studies on the registry are indexed under Premenstrual Dysphoric Disorder; 10 are open to participants now.

Browse Premenstrual Dysphoric Disorder studies →

Open to participants now

4 of the 19 studies in Premenstrual Dysphoric Disorder with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Premenstrual Dysphoric Disorder studies recruiting now, 1 sets no upper age limit and 6 stop at 75 or younger; none take children under 18; 4 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Premenstrual Dysphoric Disorder with a site in United States, or all of them as a file.
02

Study summary

Premenstrual dysphoric disorder (PMDD) is a severe affective disorder impacting millions of women worldwide, thought to be due to altered sensitivity to hormone fluctuations across the menstrual cycle. Neuroactive steroid hormones (NAS) and the gamma-aminobutyric acid (GABA)-A receptor (GABAAR) are thought to play a role in PMDD. This research will assess the blood levels of GABAergic NAS, expression of associated enzymes, and expression of GABAAR subunits across the premenstrual (luteal) phase of the menstrual cycle in healthy controls and individuals with PMDD. Within the PMDD group, the investigators will assess how these measures are affected by a low-dose antidepressant medication versus placebo. The results will provide a comprehensive view of the changes in these systems across the menstrual cycle and will add to the investigator's understanding of the mechanisms that underlie PMDD, as well as therapeutic mechanisms of PMDD treatment.

03

Conditions studied

  • Premenstrual Dysphoric Disorder (PMDD)

Keywords

  • pmdd
  • premenstrual dysphoric disorder
  • pms
  • premenstrual symptoms
  • premenstrual syndrome
  • blood draw
  • sertraline
  • ssri
  • mood symptoms
  • women
  • women with pms
  • women with pmdd
  • luteal phase
  • follicular phase
  • womens reproductive mental health
  • womens health
  • womens reproductive health
  • menstrual cycle
  • menses
  • periods
  • allopregnanolone
  • neuroactive steroids
  • inflammatory markers
  • epigenetics
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female sex,
  • fluent in the English language
  • regular menstrual cycles (24-35 days)
  • age 18-50 years old
  • ability to give written

Exclusion criteria

Exclusion Criteria:

  • psychiatric medication use in the past 2 months
  • substance use disorder in the past 6 months
  • lifetime history of psychotic disorder including schizophrenia
  • schizoaffective disorder, major depression with psychotic features
  • history of psychiatric disorder other than PMDD in past year
  • active suicidal ideation with plan or attempt in past 6 months
  • hormone or hormonal use (except levonorgestrel as emergency contraceptive) in past 2 months
  • pregnancy in past 6 months
  • history of brain injury
  • current or history of endocrine disorder including uncontrolled diabetes or thyroid disease
  • >40
  • History of arrythmias, severe liver impairment, history of seizure disorder
  • If currently taking the following meds: methylene blue, linezolid
  • Other prohibited concomitant meds are Monoamine oxidase inhibitors (MAOIs), pimozide, and disulfiram
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
288 participants (estimated)

Study arms

  • No intervention
    Control

    Participants delegated to the "control" arm will be individuals without premenstrual symptoms in the luteal phase of the menstrual cycle. Participants will be asked to track mood across the menstrual cycle, answer self-report surveys, and complete four blood draws.

  • Active comparator
    PMDD with sertraline

    Participants delegated to the "PMDD with sertraline" arm will be individuals with severe premenstrual symptoms in the luteal phase of the menstrual cycle. Participants will be asked to track mood across two menstrual cycles, answer self-report surveys, and complete eight blood draws (four in each menstrual cycle). In the second cycle, participants in this arm will take a daily pill of 50 mg of sertraline from ovulation until menses onset (end of menstrual cycle 2).

    Drug: sertraline 50 mg daily

  • Placebo comparator
    PMDD with placebo

    Participants delegated to the "PMDD with placebo" arm will be individuals with severe premenstrual symptoms in the luteal phase of the menstrual cycle. Participants will be asked to track mood across two menstrual cycles, answer self-report surveys, and complete eight blood draws (four in each menstrual cycle). In the second cycle, participants in this arm will take a daily placebo pill from ovulation until menses onset (end of menstrual cycle 2).

    Drug: Placebo Oral Tablet

Interventions

  • DrugSertralineStudies of SertralineSertraline pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The intervention will be in the form of an oral pill, taken daily, from the day of positive urine ovulation test result until the day of menses onset.

  • DrugPlacebo Oral Tablet

    The placebo oral tablet will be of the same shape, color, and manufacturer as the sertraline 50 mg oral tablets. Tablet will be taken daily, from the day of positive urine ovulation test result until the day of menses onset.

06

What researchers measure

Primary outcomes

  1. Neuroactive Steroid Levels

    The primary outcome variable is levels of neuroactive steroids in blood; from the early luteal phase (2 days post ovulation) compared to the late luteal phase (days 5 to 1 prior to predicted menses onset)

    Time frame: Post ovulation up to 2 days, up to 5 days pre-menses prediction

Secondary outcomes

  1. Neurosteroidogenic enzyme expression levels

    Neurosteroidogenic enzyme expression levels will be measured in the early luteal phase (2 days post ovulation) and the late luteal phase (days 5 to 1 prior to predicted menses onset). Levels will be compared between the healthy controls and PMDD groups at cycle 1, and between sertraline and placebo groups at cycle 2, respectively; between cycle 1 (first menstrual cycle when blood draws will be completed) and until the end of the participants' time on the study (2-3 months).

    Time frame: First menstrual cycle, up to 3 months

  2. GABAAR subunit expression levels

    GABAAR subunit expression will be measured in the early luteal phase (2 days post ovulation) and the late luteal phase (days 5 to 1 prior to predicted menses onset). The investigators will compare GABAAR subunit expression levels between controls and PMDD groups at L1, and between sertraline and placebo groups at L2, respectively; between cycle 1 (first menstrual cycle when blood draws will be completed) and until the end of the participants' time on the study (2-3 months)

    Time frame: first menstrual cycle, up to 3 months

07

Study locations

2 of 2 sites recruiting
  • Reproductive Mental Health Center
    Baltimore, Maryland 21205, United States
    Recruiting
    • Victoria N Paone, B.S. · Contactvpaone1@jh.edu · 443-685-4258
    • Liisa Hantsoo, Ph.D. · Contactlhantso1@jhmi.edu
    • Liisa Hantsoo, Ph.D. · Principal investigator
  • University of Virginia
    Charlottesville, Virginia 22903, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Jul 2029, 49 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2024
First posted
Nov 26, 2024
StartActual
May 14, 2025
Primary completionEst.
Jul 1, 2029
CompletionEst.
Jul 1, 2029
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06704594
Responsible party
Sponsor
First posted
Nov 26, 2024
Start date
May 14, 2025
Primary completion
Jul 1, 2029 (estimated)
Completion
Jul 1, 2029 (estimated)
Last update
May 7, 2026

Study contacts

Victoria Paone, B.S.
Contact
vpaone1@jh.edu
4436854258
Victoria Seo, B.S.
Contact
vseo1@jh.edu
Liisa Hantsoo, PhD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sertraline

Start the discussion